Where does Enliven Therapeutics's cash flow data come from?

Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$98.78M+4.7%	-$103.69M-6.7%	-$97.21M+3.0%	-$100.22M-5.7%	-$94.83M-6.5%
Depreciation and amortization	$203K-22.8%	$263K-11.4%	$297K-5.7%	$315K+1.0%	$312K-1.6%
Stock-based compensation	$34.62M+1.8%	$34.02M+25.8%	$27.05M+8.0%	$25.04M+11.5%	$22.46M+11.3%
Gain (loss) on sale of assets	——	-$106K-28.9%	-$82.25K-40.6%	-$58.5K-68.3%	-$34.75K-216%
Change in accounts payable	$78K-90.5%	$817K+162%	$312K—	——	——
Change in accrued liabilities	——	——	——	——	$322K+230%
Change in operating lease liabilities	-$365K-8.3%	-$337K-1.8%	-$331K-1.8%	-$325K-1.2%	-$321K+4.2%
Net cash from operating activities	-$65.47M+6.9%	-$70.3M+1.9%	-$71.67M-1.5%	-$70.58M+4.6%	-$73.96M-1.0%
Capital expenditures	——	——	——	$181K+311%	$44K0.0%
Proceeds from sale of property, plant and equipment	——	$213K+33.3%	$159.75K+50.0%	$106.5K+100%	$53.25K—
Net cash from investing activities	-$145.12M+22.1%	-$186.22M—	——	——	——
Proceeds from issuance of common stock	$12.11M+428%	$2.3M+29.9%	$1.77M+13.4%	$1.56M+566%	$234K—
Net cash from financing activities	$229.05M+4.5%	$219.24M-15.2%	$258.58M-0.4%	$259.7M+502%	$43.13M-67.6%
Net increase (decrease) in cash	——	——	——	——	-$47.51M-298%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	-$694K+59.6%	-$1.72M-65.0%	-$1.04M-145%
Depreciation	$203K-22.8%	$263K-11.4%	$297K-5.7%	$315K+1.0%	$312K-1.6%
Gain/(loss) on dispositions, net	——	-$106K-28.9%	-$82.25K-40.6%	-$58.5K-68.3%	-$34.75K-216%
Accrued expenses and other liabilities	——	——	——	——	$322K+230%
Operating lease liabilities	-$365K-8.3%	-$337K-1.8%	-$331K-1.8%	-$325K-1.2%	-$321K+4.2%
Prepaid expenses and other current assets	——	——	——	——	——
Non Cash Lease Expense	$361K+2.3%	$353K+3.2%	$342K+2.7%	$333K+2.1%	$326K+1.9%
Proceeds from disposals of property, plant and equipment	——	$213K+33.3%	$159.75K+50.0%	$106.5K+100%	$53.25K—
Proceeds From Issuance Of Common Stock Under Sales Agreement Net Of Issuance Costs	——	$0-100%	$9.8M-50.0%	$19.59M-33.3%	$29.39M-25.0%
Increase Decrease In Operating Lease Liability	-$365K-8.3%	-$337K-1.8%	-$331K-1.8%	-$325K-1.2%	-$321K+4.2%
Operating Lease Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities	——	——	——	——	$736K—
Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets	——	——	-$5K+95.8%	-$118K-136%	-$50K—
Free cash flow	-$65.6M+6.9%	-$70.46M+1.9%	-$71.82M-1.5%	-$70.76M+4.4%	-$74M-1.0%
Free cash flow	-$65.6M+6.9%	-$70.46M+1.9%	-$71.82M-1.5%	-$70.76M+4.4%	-$74M-1.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Enliven Therapeutics's cash flow data come from?: Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.